Trade Ultragenyx Pharmaceutical Inc - RARE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 37.57 |
| Open | 37.13 |
| 1-Year Change | -15.94% |
| Day's Range | 36.97 - 38.01 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 37.57 | 0.64 | 1.73% | 36.93 | 37.71 | 36.49 |
| Apr 23, 2025 | 37.25 | 1.20 | 3.33% | 36.05 | 37.72 | 36.05 |
| Apr 22, 2025 | 35.85 | 0.20 | 0.56% | 35.65 | 36.06 | 35.14 |
| Apr 21, 2025 | 35.32 | 1.31 | 3.85% | 34.01 | 37.10 | 34.01 |
| Apr 17, 2025 | 35.62 | 1.66 | 4.89% | 33.96 | 35.66 | 33.96 |
| Apr 16, 2025 | 34.93 | 0.65 | 1.90% | 34.28 | 35.05 | 34.05 |
| Apr 15, 2025 | 35.22 | 1.09 | 3.19% | 34.13 | 35.42 | 34.13 |
| Apr 14, 2025 | 34.85 | 0.30 | 0.87% | 34.55 | 35.01 | 33.74 |
| Apr 11, 2025 | 34.05 | 1.33 | 4.06% | 32.72 | 34.41 | 32.22 |
| Apr 10, 2025 | 33.11 | 0.72 | 2.22% | 32.39 | 33.43 | 31.20 |
| Apr 9, 2025 | 33.80 | 3.80 | 12.67% | 30.00 | 34.37 | 29.46 |
| Apr 8, 2025 | 31.02 | -1.40 | -4.32% | 32.42 | 33.84 | 30.12 |
| Apr 7, 2025 | 32.09 | 1.14 | 3.68% | 30.95 | 33.17 | 30.26 |
| Apr 4, 2025 | 32.41 | -1.54 | -4.54% | 33.95 | 34.44 | 32.01 |
| Apr 3, 2025 | 35.08 | 0.97 | 2.84% | 34.11 | 35.39 | 34.11 |
| Apr 2, 2025 | 35.31 | 1.85 | 5.53% | 33.46 | 35.34 | 33.46 |
| Apr 1, 2025 | 33.79 | -2.16 | -6.01% | 35.95 | 35.95 | 33.64 |
| Mar 31, 2025 | 36.18 | -0.67 | -1.82% | 36.85 | 36.86 | 35.50 |
| Mar 28, 2025 | 37.75 | -0.55 | -1.44% | 38.30 | 38.53 | 37.63 |
| Mar 27, 2025 | 38.84 | 1.42 | 3.79% | 37.42 | 39.07 | 37.42 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Ultragenyx Company profile
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ultragenyx Pharmaceutical Inc revenues increased 30% to $351.4M. Net loss increased from $186.6M to $454M. Revenues reflect Crysvita collaboration revenue in profit-share territory segment increase of 33% to $171.2M, Dojolvi segment increase from $13M to $39.6M, United States segment increase of 27% to $301.1M, others segment increase of 96% to $23.6M.
Equity composition
Common Stock, $0.001 Par, 01/14, Auth. 250M Shares., 29,061,871 issd,. Insiders owns approx. 19.82%.
| Industry: | Bio Therapeutic Drugs |
60 Leveroni Ct
NOVATO
CALIFORNIA 94949
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com